NDC 0008-0100 – Besponsa

Inotuzumab Ozogamicin .25 mg/mL · Injection, Powder, Lyophilized, For Solution · Intravenous

Human Prescription Drug

Product NDC0008-0100

Product details

Brand name
Besponsa
Generic name
Inotuzumab ozogamicin
Labeler
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Dosage form
Injection, Powder, Lyophilized, For Solution
Route
Intravenous
Marketing category
BLA · BLA761040
Marketed since
August 18, 2017
Listing expires
December 31, 2027
Pharmacologic class
CD22-directed Immunoconjugate

Active ingredients

Uses, dosage, side effects and warnings for Besponsa →

Package NDC codes (1)

Package NDCDescriptionSince
0008-0100-011 VIAL, SINGLE-DOSE in 1 CARTON (0008-0100-01) / 4 mL in 1 VIAL, SINGLE-DOSEAug 18, 2017